Although upfront surgery has been the gold standard for pancreatic adenocarcinoma that is planned for resection, it should be compared with the alternative strategy of neoadjuvant therapy. Despite the many reports of the efficacy of neoadjuvant therapy, most of them were not comparative. Recently Prep-02/JSAP05 study clearly demonstrated the significant survival benefit of neoadjuvant chemotherapy over upfront surgery for pancreatic adenocarcinoma that is planned for resection. These findings opened a new chapter of neoadjuvant therapy. Ongoing trials are expected to confirm the evidence. This review summarizes the past, present, and future perspectives of neoadjuvant therapy and its optimization. K E Y W O R D S neoadjuvant chemotherapy, neoadjuvant therapy, pancreatic adenocarcinoma, resectable pancreatic cancer
| RE S EC TAB ILIT Y OF PAN CRE ATI C ADENOC ARCINOMA
Several definitions of resectability of pancreatic adenocarcinoma (PDAC) have been approved for determining the possibility for complete clearance (R0 resection) by surgery, taking into account oncological and general aspects. [1] [2] [3] [4] Surgical resectability of PDAC is assessed by the evaluation of local tumor extension to vessels and distant metastases. Excluding tumor with distant metastases, which is defined as unresectable with metastases (UR-M), local resectability is classified in three categories: resectable (R), borderline resectable (BR), and unresectable (UR-LA). R PDAC shows no vascular infiltration to major vessels. Complete clearance of R tumor is required in standard pancreatectomy without combined vascular resection. BR PDAC is sub-classified into two categories: BR-PV showing PV distortion or narrowing, and BR-A showing semi-circumferential abutment with a major artery. There is a theoretical "borderline" between BR-PV and BR-A. Whereas PV resection is currently recommended for achieving R0 resection, 5, 6 arterial resection remains controversial due to significantly increased rates of morbidity. 6 From the surgical perspective, BR-PV PDAC is borderline resectable, whereas BR-A PDAC is borderline unresectable. Considering surgical feasibility, R and BR-PV PDAC should be considered as candidates for "PDAC that is planned for resection (potentially resectable PDAC)."
Potentially resectable PDAC has been treated by upfront surgery, 1, 2 although neoadjuvant for BR PDAC might be considered given the poor oncological outcomes. 7 
| P OTENTIALLY RE S EC TAB LE PDAC
Upfront surgery has been the gold standard for potentially resectable PDAC, as well as for most other solid cancers. Adjuvant therapy (adjuvant) is administered for macroscopically curatively resected PDAC with full recovery in the planned postoperative period and without immediate early recurrence (Figure 1 ). This cohort benefits from recent advances of adjuvant chemotherapy. Randomized controlled trials (RCTs) of adjuvant chemotherapy reported that the median overall survival (OS) these selected patients reached was 46.5 months with S1 adjuvant 8 and 54.4 months with modified FOLFIRINOX adjuvant. 9 Adjuvant for patients with resected PDAC, who are eligible after selection for surgery ( Figure 1 ), is fully accepted as the standard based on solid evidence. In contrast to eligible patients, patients with aggressive tumor (incompletely resectable, 10 immediately recurred, 11 or vulnerable for treatment (insufficiently recovered 12 ) who show a poor prognosis are excluded from analysis.
Unfortunately, it is hard to discriminate, before surgery, between eligible patients and ineligible patients for adjuvant. Since potentially resectable PDAC is not equal to resected PDAC eligible for adjuvant ( Figure 1 ), it is not convincing that upfront surgery is the optimal strategy for potentially resectable PDAC. The optimal strategy should be explored by a comparison between upfront surgery and the alternative strategy of neoadjuvant therapy (neoadjuvant) followed by surgery.
| PROS PEC TIVE S TUD IE S AND ME TA-ANALYS E S
As well as upfront surgery, neoadjuvant followed by surgery has patient selection during the neoadjuvant period, in addition to surgical selection ( They showed the superiority of combination therapy to monotherapy, with high resection and survival rates. 16 Heinrich et al 17 also reported the safety and effect of NAC with a similar regimen associated with improved quality of life and nutritional status. The survival outcome of NACRT with a combination regimen and that with monotherapy suggested that the combination regimen did not improve the outcome. 18, 19 Landry et al 20 These results are summarized in Table 1 . [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Although these studies reported the survival outcome of an ITT cohort, none of them had a cohort treated by upfront surgery as a control. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Several meta-analyses investigated the efficacy of neoadjuvant. 29 including only ITT data. 32 The results of the meta-analysis showed that the patients treated with neoadjuvant had better long-term survival than those treated with upfront surgery. Though these analyses demonstrated the improvement of survival by neoadjuvant, the results were not conclusive.
| R ANDOMIZED, CONTROLLED TRIAL S
Unfortunately to BR PDAC. 35 Although the number of cases was small, which raised some criticism of their study design and conduct, 7 39, 40 The resection rates of both arms were similar, with no operative mortality. A significant decrease of pathological nodal metastases and hepatic relapse after surgery was noted in the NAC-GS patients compared to upfront surgery patients. 40 Based on the results of this adequately powered RCT, it was concluded that the strategy of NAC-GS could be a new standard for potentially resectable PDAC. These data from RCTs are summarized in Table 2 . There were differences among the five trials, including types of intervention and eligibility for the study.
Although the survival outcomes of these trials were different, the resection rates for upfront surgery were comparable, ranging from 70% to 78%. The resection rate of NACRT, which was quite similar and ranged from 61% to 63%, [33] [34] [35] 37 was about 10% lower than that of each control. Only selected cases after neoadjuvant might benefit from NACRT intervention with its advantage for local treatment, as suggested by the PREOPANC-1 trial. 37 The resection rate after NAC did not decrease compared to that of control upfront surgery. 39, 40 In contrast to NACRT, potentially resectable PDAC could benefit from NAC due to its nature as a systemic treatment. 
| OP TIMAL PROTO COL FOR NEOADJ U VANT THER APY
Two cycles of the GS regimen, which was used in the Prep-02/ JSAP05 study, have been a standard regimen for NAC, at least in Japan, for potentially resectable PDAC. [38] [39] [40] Although several prospective trials using other regimens, which include radiotherapy, are ongoing, their results have yet been clearly reported. 36, 37, [41] [42] [43] [44] Considering recent progress in chemotherapy for UR PDAC, 45, 46 a clinical question has been raised about the optimal protocol in the neoadjuvant setting. 24 Okano K 57 R, BR S1 + RT 91% N. R. N. R. 25 Motoi F 101 R, BR GEM/S1 73% 30.8 N. R. 26 Tsai S 130 R, BR FOLFIRINOX (n = 52) FOLFIRI (n = 26) GEM/Nab-P (n = 16) CAP/Nab-P (n = 15) *+RT (n = 83) 82% 38 45 27 Eguchi H 63 R GEM/S1 + RT 86% 55.3 NR 39, 40 showed a significantly higher response rate and longer PFS than gemcitabine single-agent. 47 Ozaka et al 48 also reported similar results, with a high response rate and longer PFS, in a randomized, phase II trial. Louvet et al 41 reported that gemcitabine and oxaliplatin, which were used in a neoadjuvant study, showed a significantly higher response rate and longer PFS than gemcitabine alone. 49 Cunningham et al 50 also demonstrated a significantly higher response rate and longer PFS with combination gemcitabine plus capecitabine than with gemcitabine alone. These combination regimens might be candidates for the optimal NAC regimen, and they are summarized in Table 3 .
| THE OP TIMAL REG IMEN FOR NEOADJ U VANT CHEMOTHER APY
In the adjuvant setting, the modified FOLFIRINOX was more active than gemcitabine. 9 In a similar setting, however, gemcitabine plus nab-paclitaxel showed marginal results that were not significant Abbreviations: CAP, Capecitabine; GEM, Gemcitabine; N, Number in the cohort; Nab-P, Nab-Paclitaxel; OS, median overall survival in months of each arm; OX, Oxaliplatin; PFS, median progression-free survival in months of each arm.
with respect to recurrence-free survival compared to gemcitabine. 51 The trial comparing gemcitabine plus capecitabine to gemcitabine in the adjuvant setting (ESPAC-4) showed positive results. 52 Murakami et al 53 reported, in a retrospective analysis, that the GS regimen was active in the adjuvant setting. Given the efficacy of FOLFIRINOX in various settings, 9, 45 this regimen would be one of the most attractive candidates to be evaluated as NAC, compared with NAC-GS as a control. In any case, a well-designed RCT is necessary to explore the optimal regimen.
| CHEMOTHER APY AND/OR R ADIOTHER APY ?
Chemoradiotherapy is an attractive modality in the treatment of PDAC for local disease control. In the neoadjuvant setting, an increase of R0 resection, which would decrease local relapse after resection, is expected for NACRT. Many prospective non-randomized trials of NACRT have been reported. 14, 15, [18] [19] [20] [21] [22] 25, 27, 28 RCTs comparing NACRT with upfront surgery, however, have not yet been fully reported, [33] [34] [35] [36] [37] in contrast to NAC. [38] [39] [40] The good survival outcomes. 55 Their concept is "total neoadjuvant therapy (TNT)," an emerging approach with excellent outcomes for other cancers. 56 The group also reported the effect of TNT for UR PDAC, with excellent survival. 57 These strategies might also improve the survival outcome of R PDAC. The use of radiation should be examined, rather than assuming an either/or scenario in a prospective trial.
| OP TIMAL DUR ATI ON FOR NEOADJ U VANT
The duration of neoadjuvant was about 2 months in most previously reported trials for R PDAC. 2, 24, 26, 28, 38 A longer course of neoadjuvant might improve the survival outcome when the regimen continues to be active after the initial treatment period of 2 months. Excluding non-responders 10, 11 and also vulnerable cases, 12 the addition of effective treatment would have a good effect on tumor control. Compared to other types of cancer that are chemotherapy-or radiotherapy-sensitive, pathological complete response (CR) is rarely obtained after neoadjuvant for PDAC. 25, 28 Though two cycles of NAC-GS showed significant survival benefit for potentially resectable PDAC, 39, 40 it might not be of sufficient duration for a large proportion of PDAC patients because of its poor prognosis.
For neoadjuvant for UR and BR PDAC including the concept of "conversion surgery," several reports demonstrated longer duration of the treatment before surgery. [58] [59] [60] Longer duration of neoadjuvant would be necessary; therefore, an accurate assessment of response using appropriate surrogate markers to decide on treatment continuation would be essential to avoid detrimental elongation of the treatment. 61 and rectum. 62 In neoadjuvant for PDAC, however, pathological CR is rarely obtained even after multi-modal treatment. 25, 28, 63 Although a good pathological effect after neoadjuvant would be presumed to lead to longer survival, 64 it remains to be elucidated in the neoadjuvant setting of PDAC.
| SURROG ATE ENDP OINT FOR NEOADJ U VANT
Radiological response would be a candidate surrogate endpoint.
Radiological assessment, which could be performed before surgery, is superior to pathological assessment in clinical decision-making.
Radiological CR could reflect pathological CR, which could be a surrogate endpoint of survival in the other types of cancer described above. As well as pathological CR, radiological CR of PDAC is rarely obtained even after multi-modal treatment. 28, 55 Serum tumor markers and their kinetics are other promising candidates as surrogate endpoints. CA19-9, which is increased in most PDACs at baseline, is widely used as a tumor marker. A decrease of tumor markers after therapy reflects a good response and longer survival for responders. 64 For resected PDAC, a decrease of CA19-9
to the normal range after surgery is associated with longer survival and a low hepatic relapse rate. 65, 66 The CA19-9 level, which can be measured less-invasively and quantitatively, has several advantages as a surrogate endpoint. In a proportion of the cases with normal CA19-9 levels after surgery following neoadjuvant, CA19-9 levels would be a surrogate endpoint of survival to select an optimal regimen or duration of the treatment. However, further efforts are still needed to determine the optimal cut-off point of tumor marker as a surrogate endpoint.
| CON CLUS ION
Recently evidence opened a new chapter of the neoadjuvant era for PDAC. However, it was only a beginning, and further efforts are needed to optimize it with adequate surrogate markers. 
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